Article thumbnail

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

By Jonathan K Reynolds

Abstract

JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes, that are inadequately controlled, either by sitagliptin or metformin alone or together in free-dose combination form. Sitagliptin, an inhibitor of the enzyme DDP-4, assists patients with type 2 diabetes mellitus to achieve glycemic control. It has been shown to be safe and effective at 100 mg daily doses. The effect of giving sitagliptin in combination with metformin is thought to have a complimentary and possibly additive effect on glycemic control

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3048013
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans.
  2. (2004). Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis. Clin Ther.
  3. (2002). Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther.
  4. (1996). Clinical pharmacokinetics of metformin. Clin Pharmacokinet.
  5. (2008). Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev.
  6. (2007). Disease Control and Prevention. National Diabetes Fact Sheet,
  7. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
  8. (2007). Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab.
  9. (2007). Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care.
  10. (2001). Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care.
  11. (2007). Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care.
  12. Effect of sitagliptin on the pharmacokinetics of simvastatin.
  13. (2006). Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care.
  14. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
  15. (2008). Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract.
  16. (2008). Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab.
  17. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care.
  18. (2006). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallelgroup study. Clin Ther.
  19. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.
  20. (2007). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab.
  21. Enhanced secretion of glucagonlike peptide 1 by biguanide compounds.
  22. Evaluation of alternative strategies for optimizing glycemia: progress to date.
  23. (1997). Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
  24. (2003). Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab.
  25. (1998). Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
  26. (2004). Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin Investig Drugs.
  27. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications
  28. (2008). Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Investig Drugs.
  29. (2007). JanumetTM (sitagliptin/metformin HCl) Tablets [package insert].
  30. (2006). Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV inhibitor [abstract no. PII-49]. Clin Pharmacol Ther.
  31. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
  32. New drugs for type 2 diabetes mellitus: what is their place in therapy?
  33. (2007). Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin.
  34. (2004). Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
  35. (2007). Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc).
  36. St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
  37. The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms. Drugs. 1999; 58(Suppl 1):31–39; discussion,
  38. (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
  39. (2006). The effect of MK-0431 on the pharmakokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ther.
  40. Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update. Fundam Clin Pharmacol.
  41. (1993). Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci.